Activation of CDK1 is essential for M-phase entry both in mitosis and meiosis. G2-arrested oocytes contain a pool of CDK1/cyclin B complexes that are maintained inactive because of the phosphorylation of CDK1 on Thr14 and Tyr15 by the Wee1 family protein kinase Myt1, whose inhibition suffices to induce meiosis I entry [1] [2] [3] [4] [5] . CDK1/XRINGO and p90Rsk can both phosphorylate and downregulate Myt1 activity in vitro [6, 7] . Here we identify five p90Rsk phosphorylation sites on Myt1 that are different from the CDK1/XRINGO sites, and we show how both kinases synergize during oocyte maturation to inhibit Myt1, ensuring meiotic progression. We found that phosphorylation of Myt1 by CDK1/XRINGO early during oocyte maturation not only downregulates Myt1 kinase activity but also facilitates the recruitment of p90Rsk and further phosphorylation of Myt1. Mutation of the five p90Rsk residues to alanine impairs Myt1 hyperphosphorylation during oocyte maturation and makes Myt1 resistant to the inhibition by p90Rsk. Importantly, Myt1 phosphorylated by p90Rsk does not interact with CDK1/cyclin B, ensuring that the inhibitory phosphorylations of CDK1 cannot take place after meiosis I entry and contributing to the all-or-none meiotic response.
Summary
Activation of CDK1 is essential for M-phase entry both in mitosis and meiosis. G2-arrested oocytes contain a pool of CDK1/cyclin B complexes that are maintained inactive because of the phosphorylation of CDK1 on Thr14 and Tyr15 by the Wee1 family protein kinase Myt1, whose inhibition suffices to induce meiosis I entry [1] [2] [3] [4] [5] . CDK1/XRINGO and p90Rsk can both phosphorylate and downregulate Myt1 activity in vitro [6, 7] . Here we identify five p90Rsk phosphorylation sites on Myt1 that are different from the CDK1/XRINGO sites, and we show how both kinases synergize during oocyte maturation to inhibit Myt1, ensuring meiotic progression. We found that phosphorylation of Myt1 by CDK1/XRINGO early during oocyte maturation not only downregulates Myt1 kinase activity but also facilitates the recruitment of p90Rsk and further phosphorylation of Myt1. Mutation of the five p90Rsk residues to alanine impairs Myt1 hyperphosphorylation during oocyte maturation and makes Myt1 resistant to the inhibition by p90Rsk. Importantly, Myt1 phosphorylated by p90Rsk does not interact with CDK1/cyclin B, ensuring that the inhibitory phosphorylations of CDK1 cannot take place after meiosis I entry and contributing to the all-or-none meiotic response.
Results and Discussion
Myt1 is thought to play an important role in the G2 arrest of Xenopus oocytes [5, 8, 9] . The activity of Myt1 appears to be cell-cycle regulated because it is lower in M phase, which correlates with its hyperphosphorylation [8] [9] [10] [11] . The phosphorylation of Myt1 by XRINGO-activated CDK1 results in Myt1 inhibition [7] . This observation, together with the accumulation of XRINGO protein early during oocyte maturation [12] , suggests that XRINGO plays a triggering role in meiotic G2-M progression. However, XRINGO antisense oligonucleotides delay but do not block progesterone-induced oocyte maturation [13] , indicating that additional kinases are probably implicated in Myt1 inactivation. An excellent candidate is the p42MAPK-activated protein kinase p90Rsk, which can interact with and phosphorylate Myt1, inhibiting its activity [6] . Moreover, interfering with the activation of the p90Rsk pathway has been shown to delay meiosis I entry [14] [15] [16] [17] .
Myt1 contains two domains, the N-terminal kinase domain and the C-terminal (Ct) regulatory domain, separated by a putative membrane-anchor region [8, 9, 11] (see Figure S1A available online). Overexpression of full-length Myt1 delayed the kinetics of meiosis I entry induced by progesterone, whereas the oocytes injected with Myt1-DC, which lacks the last 210 Ct residues but retains the catalytic domain, matured with similar kinetics as mock-injected oocytes ( Figure S1B) . Moreover, the electrophoretic mobility of Myt1-DC was not retarded, suggesting that it was not hyperphosphorylated, in spite of the activation of both maturation promoting factor (MPF) and the p42MAPK pathway ( Figure S1C ). We confirmed that full-length Myt1 and Myt1-DC had similar kinase activities ( Figure S1D ), suggesting that the impaired recruitment of CDK1/cyclin B to Myt1-DC was probably responsible for its reduced ability to inhibit oocyte maturation. Taken together, these results indicate that the Ct domain is necessary for the Myt1 inhibitory function during oocyte maturation.
To test whether p90Rsk and CDK/XRINGO phosphorylate Myt1-Ct on different sites, we used the 3AP mutant ( Figure 1A) , with the three CDK/XRINGO phosphorylation sites (Ser410, Ser414, and Ser444) changed to Ala [7] , as a substrate in kinase assays. Interestingly, p90Rsk phosphorylated Myt1-Ct 3AP with similar efficiency as wild-type (WT) Myt1-Ct ( Figure 1B) . Moreover, upon phosphorylation by p90Rsk, fulllength WT Myt1 and Myt1-3AP proteins were both less efficient at inhibiting CDK1/cyclin B activity, indicating that p90Rsk also inactivated Myt1-3AP ( Figure 1C) .
Xenopus Myt1-Ct contains seven putative consensus p90Rsk phosphorylation sites, which are preceded by N-terminal Arg residues ( Figure S1E ). Using several GST-fused Myt1-Ct fragments, we found that residues Ser515 and Ser517 did not significantly contribute to Myt1 phosphorylation. Therefore, we systematically mutated to Ala the rest of the putative p90Rsk phosphorylation sites in Myt1-Ct. We found that mutation of Thr453 (TA mutant) had no effect on Myt1-Ct phosphorylation by p90Rsk. In contrast, the mutation of Ser472 and Ser475 (2A mutant) reduced the phosphorylation of Myt1-Ct by about 25%. Interestingly, the combined mutation of T453A, S472A, and S475A (2A+TA mutant) reduced the phosphorylation of Myt1-Ct by p90Rsk about 70% compared with WT Myt1-Ct. Additional mutation of Ser492 (3A mutant) and Ser504 (4A mutant), in combination with S472A and S475A, further reduced the phosphorylation of Myt1-Ct by p90Rsk to about 60% and 80%, respectively ( Figure 1D ). Finally, combination of the five mutations (5A mutant) almost completely abrogated Myt1-Ct phosphorylation by p90Rsk ( Figures 1D and 1E) , suggesting that they all contribute to the phosphorylation of Myt1 by p90Rsk. In contrast, CDK1/ XRINGO phosphorylated Myt1-Ct 5A as efficiently as WT Myt1-Ct ( Figure 1E) .
Importantly, the Myt1-Ct 5A mutant was phosphorylated to a lesser extent than WT Myt1 in progesterone-stimulated oocytes ( Figure 1F ). In particular, the late Myt1 phosphorylation was delayed and reduced, and we did not observe the marked upshift of Myt1 at meiosis I entry, in spite of the normal activation of both MPF and the p42MAPK-p90Rsk pathway ( Figure 1F ). These results implicate Thr453, Ser472, Ser475, Ser492, and Ser504 in the late phosphorylation of Myt1 during M phase. We also used a commercial antibody that recognizes phospho-Ser/Thr in the sequence RXRXXS*/T* to follow the phosphorylation of Myt1 during oocyte maturation. We confirmed that this antibody recognized p90Rsk-phosphorylated Myt1, in addition to the CDK-phosphorylated sites Ser410 and Ser414, which are both preceded by Arg residues (Figures S1F and S1G). We found that this antibody detected an early (3 hr) and a late (6-12 hr) Myt1 phosphorylation in progesteronetreated oocytes that both correlated with slower electrophoretic migration of Myt1 ( Figure 1F ). However, we could not detect any phosphorylation of Myt1-3AP with the same antibody. In contrast, Myt1-5A was phosphorylated at early but not at late times, suggesting that the CDK/XRINGO sites were only transiently phosphorylated. Finally, when the CDK/ XRINGO and p90Rsk sites were all mutated to Ala (Myt1-8A), we could not detect any Myt1 phosphorylation with this antibody. Of note, the Myt1-8A mutant was still slightly upshifted at late times ( Figure 1F ), suggesting that additional Myt1 sites might be phosphorylated in mature oocytes.
To understand the biological significance of Myt1 phosphorylation by p90Rsk, we generated a mutant version of full-length Myt1 in which the five p90Rsk sites were changed to either Ala (Myt1-5A) or Asp (Myt1-5D). Overexpression of WT Myt1 delayed the kinetics of meiosis I entry induced by progesterone, and a stronger effect was observed upon expression of Myt1-5A. In contrast, the oocytes injected with Myt1-5D matured with similar kinetics, albeit a bit slower, than mockinjected oocytes, indicating that Myt1-5D was less efficient at inhibiting progesterone-induced oocyte maturation (Figure S2A ). Consistent with these results, dephosphorylation of C, and then stimulated with progesterone. Oocytes were collected at the indicated times after progesterone stimulation, and lysates were assayed for H1K activity or analyzed by immunoblotting. Myt1-Ct was detected with Myc antibody. To detect Myt1 phosphorylation, we immunoprecipitated oocyte lysates with Myc antibody and then analyzed them by immunoblotting with a phospho-Ser/Thr antibody that recognizes the sequences RXRXXS*/T* (phospho-S/T). Molecular weights are indicated in kDa.
the inhibitory Thr14 and Tyr15 sites of endogenous CDK1 and activation of CDK1/cyclin B were both slower in the oocytes expressing WT Myt1 or Myt1-5A than in oocytes expressing Myt1-5D ( Figure S2B ). Taken together, these results suggest that phosphorylation of these five residues interferes with the inhibitory role of Myt1 in oocyte maturation. When different nonphosphorylatable Myt1 mutants were compared, we observed that overexpression of Myt1-3AP or Myt1-8A had an even stronger effect than Myt1-5A at delaying the kinetics of meiosis I entry (Figure 2A ), which correlated with both slower dephosphorylation of CDK1 on Thr14 and Tyr15 and CDK1/ cyclin B activation in those oocytes ( Figure 2B ).
Next, we confirmed that phosphorylation by full-length WT Myt1 or Myt1-5A effectively inhibited the kinase activity of CDK1/cyclin B in vitro ( Figure 2C ). In contrast, Myt1-5D was less efficient and only partially reduced CDK1/cyclin B activity (to about 40%), which was consistent with the reduced ability of this mutant to inhibit progesterone-induced oocyte maturation ( Figure S2A ). These results suggest that phosphorylation of the five p90Rsk sites regulates the ability of Myt1 to inhibit CDK1/cyclin B kinase activity. In support of this idea, incubation with recombinant active p90Rsk significantly inhibited WT Myt1 but did not affect the ability of Myt1-5A to inactivate CDK1/cyclin B ( Figure 2D ; Figure S2C ), in agreement with the phosphorylation of WT Myt1 but not Myt1-5A by p90Rsk ( Figure 2E ). On the other hand, CDK1/XRINGO inhibited the kinase activities of WT Myt1 and Myt1-5A with similar efficiencies ( Figure 2D ). Taken together, these results indicate that p90Rsk and CDK1/XRINGO phosphorylate Myt1-Ct on different sites and probably represent parallel pathways leading to Myt1 inactivation.
To determine whether Myt1 phosphorylation by CDK1/ XRINGO regulates its interaction with p90Rsk, we incubated either GST-Myt1-Ct WT or the mutants that contain the three CDK/XRINGO phosphorylation sites changed to Ala (Myt1-3AP) or to Asp (Myt1-3DP) [7] in oocyte lysates and then performed GST pull-down assays to analyze the binding of endogenous p90Rsk. In agreement with previous results [6] , we observed that Myt1-Ct associated with the active and hyperphosphorylated p90Rsk1 and p90Rsk2 present in mature oocytes, but not with the inactive and underphosphorylated p90Rsk forms present in G2-arrested oocytes ( Figure 3A) . Interestingly, the nonphosphorylatable mutant Myt1-3AP interacted less efficiently with both p90Rsk family members than WT Myt1, whereas the phosphomimetic mutant Myt1-3DP was able to bind more efficiently to p90Rsk1 and p90Rsk2 ( Figure 3A) . These results suggest that the phosphorylation of Ser410, Ser414, and Ser444 by CDK1/XRINGO facilitates the binding of p90Rsk to Myt1-Ct. Next, we addressed how p90Rsk phosphorylation impaired Myt1 activity. Previous work has shown that the Ct domain of Myt1 is involved in the recruitment of CDK1/cyclin B through an RXL motif that binds to cyclin B [8, 9] . In contrast, we found that RXL was not required for the binding of Myt1 to XRINGO ( Figure S3A ). To determine whether Myt1 phosphorylation affected its interaction with CDK1/cyclin B, we analyzed the binding of different GST-Myt1-Ct phosphorylation mutants to the endogenous CDK1 from oocyte lysates. We found that the majority of the CDK1 that associated with Myt1 probably corresponded to cyclin B-bound CDK1, which is phosphorylated on Thr14 and Tyr15 ( Figure 3B) . Interestingly, the only Myt1 mutant that was impaired in CDK1 binding was Myt1-5D, suggesting that the sites phosphorylated by p90Rsk regulate the interaction between Myt1-Ct and CDK1. Further analysis indicated that Myt1-Ct needs to be phosphorylated by p90Rsk in at least four residues to release CDK1/cyclin B ( Figure 3B) . Previous studies have shown that Myt1 only phosphorylates CDK1 when it is bound to cyclin B [18] , and we confirmed that endogenous cyclin B2 coprecipitated with CDK1 in the GST-Myt1 pull downs ( Figure 3B ). These results are in agreement with previous work [8] , suggesting that the phosphorylation status of Myt1 regulates its binding to CDK1/cyclin B.
We also investigated whether p90Rsk could downregulate Myt1 catalytic activity. As shown above ( Figure 2C ), Myt1-5D was less effective than Myt1-WT at inactivating CDK1/cyclin B in vitro. However, we found no obvious differences in Myt1 autophosphorylation, as a reporter of kinase activity [19] , between Myt1-5D and WT Myt1 (Figure S3B ), suggesting that p90Rsk phosphorylation might have a small effect on Myt1 kinase activity. In contrast, the autophosphorylation ability of Myt1-3DP was significantly impaired, suggesting that CDK1/XRINGO phosphorylation inhibits Myt1 kinase activity, in agreement with previous work [7] . Moreover, incubation with Myt1-Ct 3DP, but not with the WT protein, inhibited full-length Myt1 autophosphorylation ( Figure S3C ), suggesting that direct interaction between the CDK1/XRINGO phosphorylated Ct residues and the catalytic domain of Myt1 may inhibit its kinase activity.
To further understand the regulation of Myt1 during oocyte maturation, we expressed several phosphorylation mutants in oocytes, which were then treated with progesterone, and assayed the kinase activities of the Myt1 mutants in immunoprecipitates ( Figure 4A ). We found that the WT, 3AP, 5A, and 8A Myt1 proteins were all able to inactivate CDK1/cyclin B in vitro. However, during the G2-M transition, WT Myt1 was partially inactivated, which correlated with its phosphorylation by CDK1/XRINGO (see Figure 1F) , whereas Myt1-3AP C. GST pull downs were analyzed by immunoblotting with p90Rsk1, p90Rsk2, or GST antibodies. An aliquot of the total lysates (TL) was also analyzed by immunoblotting. (B) GST-Myt1-Ct proteins (6 mg), either WT or the indicated mutants (designated as in Figure 1A but changed to either Asp or Ala), were incubated with lysates from G2-arrested oocytes during 3 hr at 4 C. GST pull downs were analyzed by immunoblotting with CDK1, cyclin B2, and GST antibodies. The upper CDK1 band corresponds to cyclin B-bound CDK1 phosphorylated on Thr14 and Tyr15. remained active. Myt1-5A was also transiently inactivated, and Myt1-8A behaved similarly to Myt1-3AP. At later times, when the majority of mock-injected oocytes had entered meiosis I, Myt1-WT was fully phosphorylated and inactivated (Figure 4A ). Myt1-3AP remained active because it was phosphorylated by neither CDK1/XRINGO nor p90Rsk, which cannot be recruited to Myt1 in the absence of CDK1/XRINGO phosphorylation. Myt1-5A also remained active, consistent with the lack of phosphorylation on CDK1/XRINGO sites because of the transient nature of these phosphorylations ( Figure 1F ). As expected, Myt1-8A was also active as a result of the lack of phosphorylation by both CDK1/XRINGO and p90Rsk. It should be noted that because of the small percentage of oocytes injected with Myt1-8A that matured upon progesterone stimulation (see Figure 2A) , it is difficult to know whether Myt1-8A could be inactivated in mature oocytes by CDK1/XRINGO and p90Rsk-independent mechanisms.
We also analyzed the binding of the different Myt1 mutants to endogenous CDK1 and found that underphosphorylated Myt1 was constitutively bound to CDK1 in G2 oocytes ( Figure 4A ). When oocytes entered M phase, only Myt1-WT released CDK1. However, Myt1-3AP, which cannot be phosphorylated by CDK1/XRINGO and does not recruit p90Rsk, as well as Myt1-5A and Myt1-8A, which both have the p90Rsk phosphorylation sites mutated, all remained bound to CDK1 ( Figure 4A ). We conclude that Myt1 is first transiently phosphorylated by CDK1/XRINGO and partially inactivated, and then p90Rsk is recruited and phosphorylates five additional sites, inducing the release of CDK1/cyclin B from Myt1, which allows full CDK1/cyclin B activation.
Our results indicate that XRINGO and p90Rsk are both required for the correct timing of MPF activation and meiosis I entry in oocytes. We propose the following sequence of events during oocyte maturation ( Figure 4B ). In G2-arrested oocytes, Myt1 is active, and stimulation with progesterone induces the early accumulation of XRINGO protein [12] , which binds to and activates monomeric CDK1. The CDK1/XRINGO complex phosphorylates Myt1 on three Ser residues, downregulating its catalytic activity. This inhibition is probably mediated by the interaction between the phosphorylated Ct and the kinase domain of Myt1. The p90Rsk pathway also becomes activated in maturing oocytes, albeit later than XRINGO accumulation, and active p90Rsk is recruited to CDK1/XRINGO-phosphorylated Myt1. CDK1/XRINGO phosphorylation might not be absolutely required for the phosphorylation of Myt1 by p90Rsk, although the phosphorylated sites probably facilitate Myt1-p90Rsk association. Then p90Rsk phosphorylates five residues on Myt1, which interfere with its binding to CDK1/cyclin B, maybe by electrostatic repulsion or by changing the Myt1 protein conformation, facilitating the activation of CDK1/cyclin B by Cdc25-mediated dephosphorylation. This mechanism resembles the role of p90Rsk in the modulation of Emi2 activity during meiosis II arrest. In that case, p90Rsk binds to CDK-phosphorylated Emi2 and further phosphorylates Emi2, promoting the recruitment of PP2A, which then dephosphorylates Emi2 sites that control binding to the anaphase-promoting complex/cyclosome [20] .
The reduced affinity of p90Rsk-phosphorylated Myt1 for CDK1/cyclin B should also contribute to the irreversibility of MPF activation. In particular, cyclin B synthesis is strongly upregulated during oocyte maturation [21] , and the newly formed CDK1/cyclin B complexes would not be inhibited by Myt1, ensuring the generation of optimal levels of MPF activity required to drive meiotic progression.
Experimental Procedures
Oocyte Maturation and mRNA Expression Xenopus oocytes were obtained from primed frogs, and meiotic maturation was induced by incubation of manually dissected oocytes with 5 mg/ml (15 mM) of progesterone (Sigma) and was scored by the appearance of a white spot at the animal pole of the oocytes, which indicates germinal vesicle breakdown and meiosis I entry. For expression of Myc-tagged proteins, oocytes were microinjected with 50 nl of in vitro transcribed mRNAs (mMessage mMachine kit, Ambion) and maintained overnight in modified Barth's medium at 18 C before progesterone treatment. For the preparation of lysates, oocytes were homogenized in 10 ml per oocyte of ice-cold H1K buffer (80 mM b-glycerophosphate, pH 7.5, 20 mM EGTA, 15 mM MgCl 2 , 1 mM DTT, 1 mM AEBSF, 2.5 mM Benzamidine, and 10 mg/ml each of Aprotinin and Leupeptin). The lysates were centrifuged at 10,000 3 g for 10 min, and the cleared supernatants were stored at 270 C.
Myt1 Kinase Activity Assays
Myt1 kinase assays were performed exactly as described [7] , by incubating Myc-tagged Myt1 proteins immunoprecipitated from microsomal membrane-supplemented reticulocyte lysates with recombinant coexpressed CDK1-cyclin B1-Cak1/Civ1 and histone H1. Samples were analyzed by SDS polyacrylamide gel electrophoresis (SDS-PAGE) and autoradiography.
To determine the effect of XRINGO-activated CDK1 on Myt1 kinase activity, we preincubated the immunoprecipitated Myt1 with active recombinant CDK1/XRINGO for 45 min at room temperature (RT) in 30 ml of H1K buffer supplemented with 350 mM ATP and then washed it at least three times with H1K buffer before incubation with the CDK1/cyclin B1 substrate. To determine the effect of p90Rsk phosphorylation on Myt1 activity, we preincubated the Myt1 immunocomplexes with recombinant active p90Rsk-EE [22] for 45 min at RT in 30 ml of S6 kinase buffer (50 mM MOPS [pH 7.2], 1 mM DTT, 10 mM MgCl 2 , 10 mM p-nitrophenylphosphate, 1 mM NaVO 3 , 10 mg/ml Leupeptin, 10 mg/ml Aprotinin, 100 mM PMSF or AEBSF) supplemented with 350 mM ATP and then washed them at least three times with H1K buffer before incubation with CDK1/cyclin B1.
Myt1 autophosphorylation was assayed by directly incubating the beadbound Myt1 immunocomplexes with H1K buffer containing 8 mCi of [g-32 P]ATP for 2 hr at 30 C. Samples were finally boiled in sample buffer and analyzed by SDS-PAGE and autoradiography.
The effect of the Ct domain on Myt1 catalytic activity was determined by preincubating the bead-bound Myt1 immunocomplexes with GST-Myt1-Ct either WT or mutant 3DP at RT. After 30 min, Myt1 autophosphorylation was assayed as above.
To assay the activity of Myt1 proteins expressed in Xenopus oocytes, we immunoprecipitated Myc-tagged Myt1 proteins as described [6] with 10 ml of Myc beads. After 3 hr, the bead-bound Myt1 immunocomplexes were washed three times in IP buffer and twice with H1K buffer and then incubated in 20 ml of kinase buffer containing 350 mM ATP and 120 ng of recombinant coexpressed CDK1-cyclin B1-Cak1/Civ1. After 60 min at RT, the CDK1/cyclin B1 activity was assayed with 4 mg of histone H1 and 2 mCi of [g-32 P]ATP for 15 min at 30 C. Samples were finally boiled in sample buffer and analyzed by SDS-PAGE and autoradiography.
For quantifications, we used a Phosphorimager (Storm 820, Molecular Dynamics) to collect radioactive emissions; computer images were analyzed with the volume integration method of the ImageQuant software.
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